An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis

Fogueri, Uma; Charkoftaki, Georgia; Roda, Gavriel F.; Tuey, Stacey; Ibrahim, Mustafa; Persaud, Indushekhar; Wempe, Michael F.; Brown, Jared M.; Thurman, Joshua M.; Anchordoquy, Thomas J.; Joy, Melanie S.

doi:10.1007/s13346-021-01022-4

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacokinetics of nanoformulations showed changes in pharmacokinetic parameters, indicating a decrease in toxicity potential to imatinib mesylate. Compared to naked drugs, MRL/MpJ-Faslrp mice receiving nanoformulations had a threefold increase in renal deposition of imatinib mesylate after 4 h [ 135 ]. Polydopamine (PDA) is rich in phenolic groups, which can eliminate ROS produced in inflammatory reactions [ 136 ] and has a strong absorption ability in the near-infrared region.…”

Section: Application Of Nanomaterials In Gn Treatmentmentioning

confidence: 99%

Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives

Zhan,

Zhang,

Chen

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Glomerulonephritis (GN) is the most common cause of end-stage renal failure worldwide; in most cases, it cannot be cured and can only delay the progression of the disease. At present, the main treatment methods include symptomatic therapy, immunosuppressive therapy, and renal replacement therapy. However, effective treatment of GN is hindered by issues such as steroid resistance, serious side effects, low bioavailability, and lack of precise targeting. With the widespread application of nanoparticles in medical treatment, novel methods have emerged for the treatment of kidney diseases. Targeted transportation of drugs, nucleic acids, and other substances to kidney tissues and even kidney cells through nanodrug delivery systems can reduce the systemic effects and adverse reactions of drugs and improve treatment effectiveness. The high specificity of nanoparticles enables them to bind to ion channels and block or enhance channel gating, thus improving inflammation. This review briefly introduces the characteristics of GN, describes the treatment status of GN, systematically summarizes the research achievements of nanoparticles in the treatment of primary GN, diabetic nephropathy and lupus nephritis, analyzes recent therapeutic developments, and outlines promising research directions, such as gas signaling molecule nanodrug delivery systems and ultrasmall nanoparticles. The current application of nanoparticles in GN is summarized to provide a reference for better treatment of GN in the future. Graphical Abstract

show abstract

Section: Application Of Nanomaterials In Gn Treatmentmentioning

confidence: 99%